Decoding Australia's TGA Regulations

Thinking about launching a health product, dietary supplement, or digital health solution in the Australian market? You might want to hit pause before assuming your U.S. or European regulatory strategy will translate. In this episode of the KF Deep Dive, host Daran Carney connects with Isabelle Petour, Principal of Launchpad Regulatory, a boutique regulatory affairs firm based in Sydney. Together, they pull back the curtain on Australia's Therapeutic Goods Administration (TGA) and explore the fascinating, often surprising realities of navigating compliance down under.

Isabelle explains how the TGA’s uniquely strict definition of a "therapeutic good" instantly converts everyday Western cosmetics and food supplements into heavily regulated medicines. She dives into the strict form-factor rules—like why a simple liquid syrup can be labeled a food, but pressing that exact same liquid into a solid tablet immediately mandates a pharmaceutical drug listing. The conversation also uncovers how a lean agency of only a few hundred people achieves world-class oversight through global reliance programs like the PIC/S GMP guides and the five-nation Access Consortium. Whether you're exploring traditional Ayurvedic medicines, managing corporate firewalls between sales and medical affairs, or bracing for the TGA's ruthless "two-week window" compliance audits, this episode is your ultimate survival guide for the Australian healthcare market.

What You'll Learn in This Episode:

• The Food-Drug Interface: How the TGA applies the definition of therapeutic claims to capture and regulate performance-enhancing products and supplements.
• The Solid Oral Dosage Trap: Why the TGA automatically classifies tablets and capsules as therapeutic goods based on domestic choking risks and kitchen safety metrics.
• Global Reliance Networks: How the TGA leverages the Access Consortium (Australia, Canada, UK, Singapore, Switzerland) to split the labor of drug evaluations and fast-track global approvals.
• The Two-Week Audit Threat: Why sponsors of traditional and listed medicines must keep their scientific evidence ready on-hand, and the reality of random compliance sampling.
• Medical Affairs Governance: The rigid operational firewalls required by the Medicines Australia Code of Conduct to separate commercial sales from clinical discussions.